Table 3—

Effects of treatment on concentrations of inflammatory markers in blood

PlaceboSM50FP250
MPO µg·L−1302.0 (149–915)249.0 (166–1274)*286.0 (134–759)
ECP µg·L−117.2 (6–56)13.7 (7–47)14.1 (4–35)
sE-selectin ng·L−147.4 (18–147)39.5 (17–93)*39.1 (19–103)
sICAM-1 ng·L−1260 (176–452)261 (195–469)248 (187–534)*
sVCAM-1 ng·L−1565 (389–681)533 (345–766)518 (355–798)#
  • Data are presented as median (range). Treatment with salmeterol 50 µg powder b.d. (SM50) significantly reduced a neutrophil-related marker and relevant adhesion molecule, whereas fluticasone propionate 250 µg powder b.d. (FP250) reduced levels of adhesion molecules important to the tissue accumulation of eosinophils.

  • MPO: neutrophil myeloperoxidase

  • ECP: eosinophil cationic protein; sE-selectin: soluble E-selectin

  • sICAM-1: soluble intercellular adhesion molecule-1

  • sVCAM-1: soluble vascular cell adhesion molecule-1

  • *: p<0.05 versus placebo

  • #: p<0.05 versus SM50